Article Details

COVID outpatients don't benefit from hydroxychloroquine, lopinavir-ritonavir

Retrieved on: 2021-04-22 19:35:41

Tags for this article:

Click the tags to see associated articles and topics

COVID outpatients don't benefit from hydroxychloroquine, lopinavir-ritonavir. View article details on hiswai:

Excerpt

A randomized, controlled trial of 685 adult COVID-19 outpatients in Brazil finds that neither the antimalaria drug hydroxychloroquine nor the antiviral ...

Article found on: www.cidrap.umn.edu

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo